Page 6 of 177: studies 51 to 60 of 1,765, newest first. Back to the neuroplasticity overview
Berkeley Scientific Journal November 13, 2025 Ana Sofia Brito
Interview with Dr. Andrea Gomez
Open Science Framework October 20, 2025 Natalia Fernandez‐Vinson, Roger Atkins, Marcus J. Glennon et al. preprint
This study examines the existence and mechanistic underpinnings of lasting neural, cognitive, and behavioural plasticity in response to N-N-dimethyltryptamine (DMT) in a hazardous drinking population. It combines behavioural, neuroimaging, ecological momentary and qualitative data to gain a holistic understanding of potential mechanisms of therapeutic change following DMT. Primarily, we test...
Research Square October 10, 2025 Gitte M. Knudsen, Annette Johansen, Pontus Plavén-sigray et al. preprint
Abstract Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiological mechanisms and impact of environmen-tal context remain unclear. Here, we tested whether a single dose of psilocybin alters synap-tic density in healthy individuals and whether setting-dependent subjective experience shapes this effect. Fifteen...
eNeuro October 1, 2025 Tanner L. Anderson, Artin Asadipooya, Pavel I. Ortinski 3 citations
Psychedelic drugs have garnered increasing attention for their therapeutic potential in treating a variety of psychiatric diseases, such as depression, anxiety, and substance use disorder. The claustrum (CLA), a brain area with remarkable interconnectivity to frontal cortices, has recently been shown to have a dense population of serotonin 2 receptors (5-HT2Rs) that are activated by...
September 27, 2025 A. N. Fedorov
Major depression affects about 280 million people worldwide and costs around 326 billion dollars per year in the United States, though the standard medications take 2-3 months to take effect, so faster and longer-lasting treatments are needed.Serotonergic psychedelics such as psilocybin, DMT or ayahuasca, LSD, and mescaline can reduce depression and anxiety symptoms after only one or two doses,...
Trials September 25, 2025 Anna Trippel, Ladina P Gubser, Etna Engeli et al. 1 citation
BACKGROUND: Cocaine is the most frequently used stimulant worldwide, with increasing consumption rates in Europe. Cocaine use is associated with great harm to individuals and society. As of today, psychotherapeutic interventions for cocaine use disorder (CUD) demonstrate only modest effect sizes, and no pharmacotherapy has been approved due to gaps in understanding the disease. However, a novel...
World Journal of Psychiatry September 19, 2025 Guo-Guang Zhao, Jing Zhao, Yan Kong et al.
Background: Treatment-resistant depression (TRD) has a poor response to clinical treatment. Patients with TRD do not respond adequately to standard antidepressants. Even after receiving a full dose and sufficient duration of combined antidepressant therapy, significant improvement is still difficult to achieve. At present, electroconvulsive therapy (ECT) remains a clinically effective method...
TIPS - Trends in Pharmacological Sciences September 16, 2025 Sonia Sonda, Diana Pendin, Stefano Comai et al. 11 citations
Psilocybin, a serotonergic psychedelic, is gaining attention for its rapid and sustained therapeutic effects in depression and other hard-to-treat neuropsychiatric conditions, potentially through its capacity to enhance neuronal plasticity. While its neuroplastic and therapeutic effects are commonly attributed to serotonin 2A (5-HT 2A ) receptor activation, emerging evidence reveals a more...
ACS Pharmacology & Translational Science September 12, 2025 Junjie Zhang, Xiubo Du, Xinying Li et al.
Hypoxia and psychedelics, despite their distinct origins, both induce altered states of consciousness and promote neuroplasticity, suggesting a shared underlying mechanism relevant to neuropsychiatric treatment and neurological recovery. Terminal lucidity, the transient resurgence of cognitive function in late-stage dementia, highlights the brain's latent capacity for rapid reorganization, a...
Psychoactives September 2, 2025 Kerem Kemal Soylemez, Emma Marie de Boo, Aysil Susuzlu et al. 2 citations
Dementia is a progressive neurodegenerative disease which is characterised by cognitive decline, memory loss, and behavioural changes. Patients suffering from dementia often experience emotional distress, sadness and depression which also impacts the wellbeing of their caregivers. Recent research has explored the potential of psychedelics, such as psilocybin and LSD, when treating various...